← SynDRA
LENVATINIB
SynDRA canonical compound SYN0024932 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | KIT |
|---|
| Mechanism of action | VEGFR inhibitor |
|---|
| Indication | thyroid cancer |
|---|
| Disease area | oncology |
|---|
All known targets
- KDR
- FLT4
- FLT1
- FGFR1
- KIT
- RET
- PDGFRB
- PDGFB
- MAPKAPK2
- NQO2
- ABL1
- PDGFRA
Mechanisms of action (all sources)
- KIT INHIBITOR
- FGFR inhibitor
- PDGFR inhibitor
- VEGFR inhibitor
- FLT1 INHIBITOR
- Vascular endothelial growth factor receptor inhibitor
- FLT4 INHIBITOR
- KDR INHIBITOR
- PDGFR tyrosine kinase receptor inhibitor
- RET INHIBITOR
- PDGFRA INHIBITOR
- FGFR1 INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- PDE4A
- YES1
- SLC6A3
- SYK
- OPRM1
- PDE3A
- PASK
- PAK4
- PAK2
- PAICS
- AAK1
- OPA1
- PDXK
- NUAK2
- NLK
- NEK9
- NEK7
- NEK3
- OLA1
- PEBP1
- NEK1
- PFKP
- PRKACG
- PRKACB
- PRKACA
- PRKAA1
- PLK4
- PKN3
- PKN2
- PKN1
- PKMYT1
- PIP4K2C
- PIP4K2A
- PIM1
- PHKG2
- PGRMC1
- PGR
- NEK2
- NDUFA13
- PRKAG2
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- ATXN2
- CCDC6
- CP2C9
- CP3A7
- KIF5B
- KSYK
- NCOA4
- TP53
Drug classes
- Receptor Tyrosine Kinase Inhibitors
- Antineoplastic Agents
- Enzyme Inhibitors
- Protein Kinase Inhibitors
- Kinase Inhibitor
ATC classes
- L01E · PROTEIN KINASE INHIBITORS
Cross-references
Synonyms
- LENVIMA
- Lenvima
- E 7080
- lenvima
- ER-203492-00
- E7080
- lenvatinib mesylate
- lenvatinib mesilate
- E-7080
- Kisplyx
- E-7080, E7080
- E7080 (Lenvatinib)
- Lenvatinib (E7080)
- Lenvatinib free base
- UNII-EE083865G2
- CHEMBL1289601
- CHEBI:85994
- 417716-92-8 (free base)
- EE083865G2
- Lenvatinib [USAN]
- Lenvatinib [USAN:INN]
- LEV
- Lenvatinib; E7080
- LENVATINIB [MI]
- Lenvatinib base- Bio-X
- LENVATINIB [INN]
- Lenvatinib (USAN/INN)
- LENVATINIB [WHO-DD]
- MLS006011239
- SCHEMBL864638
- GTPL7426
- AMY9240
- DTXSID50194605
- EX-A249
- BCPP000247
- HMS3244A07
- HMS3244A08
- HMS3244B07
Reported adverse events
- Alopecia
- Arthralgia
- Constipation
- Dehydration
- Dizziness
- Dry mouth
- Dysgeusia
- Dyspepsia
- Dysphonia
- Fatigue
- Headache
- Hepatotoxicity
Look up LENVATINIB in the interactive SynDRA portal →